Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  IGI LABORIGI       

IGI LABORIGI
Mes dernières consult.
Most popular
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 79,3 M
EBIT 2017 7,39 M
Net income 2017 -2,93 M
Debt 2017 72,1 M
Yield 2017 -
Sales 2018 119 M
EBIT 2018 18,5 M
Net income 2018 7,12 M
Debt 2018 70,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 60,18
EV / Sales2017 5,53x
EV / Sales2018 3,67x
Capitalization 366 M
More Financials
Company
Teligent, Inc. develops, manufactures and markets topical formulations.The company sells generic topical pharmaceutical products under IGI label.It also provides development, formulation, and manufacturing services to the pharmaceutical, over-the-counter and cosmetic markets.The company's products... 
Sector
Pharmaceuticals
Calendar
10/26Earnings Release
More about the company
Surperformance© ratings of IGI LABORIGI
Trading Rating : Investor Rating :
More Ratings
Latest news on IGI LABORIGI
09/20 TELIGENT : Announces FDA Approval of Triamcinolone Acetonide Cream USP, 0.1%
09/19 Teligent, Inc. Announces FDA Approval of Triamcinolone Acetonide Cream USP, 0..
09/18 TELIGENT, INC. (NASDAQ : TLGT) Files An 8-K Departure of Directors or Certain Of..
09/18 TELIGENT, INC. : Change in Directors or Principal Officers, Other Events, Financ..
09/18 Teligent, Inc. Appoints Thomas J. Sabatino, Jr. to Board of Directors
09/12 Teligent, Inc. to Present at Morgan Stanley 15th Annual Global Healthcare Con..
08/23 TELIGENT : Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%, Emo..
08/22 TELIGENT : Receives Fourth FDA Approval on 2017
08/22 Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.0..
08/08 TELIGENT : reports 2Q loss
More news
Sector news : Pharmaceuticals - NEC
09/24 SAP to buy customer management software firm Gigya
09/22DJCorrection to Sept. 7 Harvey Rebuilding Article
09/22 Korea tensions keep European shares in check before Germany vote
09/22 Bettencourt death stirs speculation about L'Oreal ownership
09/22 China online insurer ZhongAn prices Hong Kong IPO at top end, raises $1.5 bil..
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 9,40 $
Spread / Average Target 37%
EPS Revisions
Managers
NameTitle
Jason Grenfell-Gardner President, Chief Executive Officer & Director
James Charles Gale Chairman
Jenniffer L. Collins CFO, Secretary & Head-Investor Relations
Stephen Richardson Chief Scientific Officer
Nadya Lawrence Senior Vice President-Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
IGI LABORIGI366
JOHNSON & JOHNSON14.36%352 651
NOVARTIS12.62%224 990
ROCHE HOLDING LTD.6.62%220 358
PFIZER10.75%214 146
MERCK AND COMPANY11.43%177 633